Similar articles

• Prophylactic chemotherapy following breast cancer: a personal experience.

  Marchant J. Marchant J. Nurs Times. 1977 Jul 7;73(27):1050-1. Nurs Times. 1977. PMID: 196261 No abstract available.
• [Factors predictive of chemotherapy resistance in patients with breast cancer].

  Dumontet C. Dumontet C. Ann Pathol. 2000;20 Suppl:S94. Ann Pathol. 2000. PMID: 11261312 French. No abstract available.
• Effects of different progestogens on human breast tumor cell growth.

  Chen FP, Chien MH, Chen HY, Ng YT. Chen FP, et al. Climacteric. 2011 Jun;14(3):345-51. doi: 10.3109/13697137.2010.548565. Epub 2011 Mar 5. Climacteric. 2011. PMID: 21375453
• [High dose chemotherapy in ovarian and breast adenocarcinoma with poor prognosis].

  Lotz JP, Gligorov J, Selle F, Lefevre G, Pautier P, Lhommé C. Lotz JP, et al. Gynecol Obstet Fertil. 2000 Sep;28(9):620-31. Gynecol Obstet Fertil. 2000. PMID: 11075500 Review. French. No abstract available.
• Paraneoplastic neurological syndromes and breast cancer. Regression of paraneoplastic neurological sensorimotor neuropathy in a patient with metastatic breast cancer treated with capecitabine: a case study and mini-review of the literature.

  Minisini AM, Pauletto G, Bergonzi P, Fasola G. Minisini AM, et al. Breast Cancer Res Treat. 2007 Oct;105(2):133-8. doi: 10.1007/s10549-006-9444-0. Epub 2006 Nov 23. Breast Cancer Res Treat. 2007. PMID: 17123150 Review.